MichaelJoelKaneMD
Oncology • Willimantic, CTBreast Cancer, Gastrointestinal Cancer, Hematologic Oncology, Melanoma
Associate Clinical Professor, Oncology, UMDNJ - Robert Wood Johnson Medical School
Dr. Kane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
112 Mansfield Avenue
Willimantic, CT 06226Phone+1 860-456-9116- Is this information wrong?
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1986 - 1988
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 1984 - 1986- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHInternship, Internal Medicine, 1983 - 1984
Rutgers New Jersey Medical SchoolClass of 1983
Certifications & Licensure
NY State Medical License 1986 - Present
CT State Medical License 2018 - 2024
PA State Medical License 1984 - 2021
NJ State Medical License 1990 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow American College of Physicians
Clinical Trials
- Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
- Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Publications & Presentations
PubMed
- Transdermal estradiol in castrate and chemotherapy resistant prostate cancer.Stein, M., Goodin, S., Doyle-Lindrud, S., Silberberg, J., Kane, M., Metzger, D., Eddy, S., Shih, W., DiPaola, R. S.> ;Med Sci Monit. 2012 Apr
- Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.Mehnert JM, Tan AR, Moss R, Poplin E, Stein MN, Sovak M, Levinson K, Lin H, Kane M, Gounder M, Lin Y, Shih WJ, White E, Rubin EH, Karantza V> ;Mol. Cancer Ther.. 2011-08-01
Press Mentions
FDA’s Naming Rule for Biosimilars Has Undermined Congress and Health CareOctober 4th, 2021- Connecticut's Top Doctors 2021: Over 1,500 Physicians in 66 SpecialtiesJune 1st, 2021
Professional Memberships
- Member
Hospital Affiliations
Lawrence + Memorial HospitalNew London, Connecticut
The William W. Backus HospitalNorwich, Connecticut- Windham HospitalWillimantic, Connecticut
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
